These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37952690)

  • 1. CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease.
    Zuo F; Wang Y; Xu X; Ding R; Tang W; Sun Y; Wang X; Zhang Y; Wu J; Xie Y; Liu M; Wang Z; Yi F
    Metabolism; 2024 Jan; 150():155724. PubMed ID: 37952690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCDC92 promotes podocyte injury by regulating PA28α/ABCA1/cholesterol efflux axis in type 2 diabetic mice.
    Zuo FW; Liu ZY; Wang MW; Du JY; Ding PZ; Zhang HR; Tang W; Sun Y; Wang XJ; Zhang Y; Xie YS; Wu JC; Liu M; Wang ZY; Yi F
    Acta Pharmacol Sin; 2024 May; 45(5):1019-1031. PubMed ID: 38228909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of PCSK9 in glomerular lipid accumulation and renal injury in diabetic kidney disease.
    Wu M; Yoon CY; Park J; Kim G; Nam BY; Kim S; Park JT; Han SH; Kang SW; Yoo TH
    Diabetologia; 2024 Sep; 67(9):1980-1997. PubMed ID: 38879617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
    He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
    Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PFKP Activation Ameliorates Foot Process Fusion in Podocytes in Diabetic Kidney Disease.
    Zhang Z; Liang W; Luo Q; Hu H; Yang K; Hu J; Chen Z; Zhu J; Feng J; Zhu Z; Chi Q; Ding G
    Front Endocrinol (Lausanne); 2021; 12():797025. PubMed ID: 35095764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism.
    Fu Y; Sun Y; Wang M; Hou Y; Huang W; Zhou D; Wang Z; Yang S; Tang W; Zhen J; Li Y; Wang X; Liu M; Zhang Y; Wang B; Liu G; Yu X; Sun J; Zhang C; Yi F
    Cell Metab; 2020 Dec; 32(6):1052-1062.e8. PubMed ID: 33186558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirt6 ameliorates high glucose-induced podocyte cytoskeleton remodeling via the PI3K/AKT signaling pathway.
    Zhang Z; Huang H; Tao Y; Liu H; Fan Y
    Ren Fail; 2024 Dec; 46(2):2410396. PubMed ID: 39378103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-4645-3p attenuates podocyte injury and mitochondrial dysfunction in diabetic kidney disease by targeting Cdk5.
    Zhang Y; Xia S; Tian X; Yuan L; Gao Y; Liu D; Qi H; Wang S; Liu Z; Li Y; Zhao Z; Liu W
    FASEB J; 2024 May; 38(10):e23668. PubMed ID: 38742811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RIPK3 causes mitochondrial dysfunction and albuminuria in diabetic podocytopathy through PGAM5-Drp1 signaling.
    Kang JS; Cho NJ; Lee SW; Lee JG; Lee JH; Yi J; Choi MS; Park S; Gil HW; Oh JC; Son SS; Park MJ; Moon JS; Lee D; Kim SY; Yang SH; Kim SS; Lee ES; Chung CH; Park J; Lee EY
    Metabolism; 2024 Oct; 159():155982. PubMed ID: 39089491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.
    Falkevall A; Mehlem A; Palombo I; Heller Sahlgren B; Ebarasi L; He L; Ytterberg AJ; Olauson H; Axelsson J; Sundelin B; Patrakka J; Scotney P; Nash A; Eriksson U
    Cell Metab; 2017 Mar; 25(3):713-726. PubMed ID: 28190774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STING deletion alleviates podocyte injury through suppressing inflammation by targeting NLRP3 in diabetic kidney disease.
    Yang X; Chen Z; Luo Z; Yang D; Hao Y; Hu J; Feng J; Zhu Z; Luo Q; Zhang Z; Liang W; Ding G
    Cell Signal; 2023 Sep; 109():110777. PubMed ID: 37329999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podocyte Injury in Diabetic Kidney Disease in Mouse Models Involves TRPC6-mediated Calpain Activation Impairing Autophagy.
    Salemkour Y; Yildiz D; Dionet L; 't Hart DC; Verheijden KAT; Saito R; Mahtal N; Delbet JD; Letavernier E; Rabant M; Karras A; van der Vlag J; Nijenhuis T; Tharaux PL; Lenoir O
    J Am Soc Nephrol; 2023 Nov; 34(11):1823-1842. PubMed ID: 37678257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPR43 activation-mediated lipotoxicity contributes to podocyte injury in diabetic nephropathy by modulating the ERK/EGR1 pathway.
    Lu J; Chen PP; Zhang JX; Li XQ; Wang GH; Yuan BY; Huang SJ; Liu XQ; Jiang TT; Wang MY; Liu WT; Ruan XZ; Liu BC; Ma KL
    Int J Biol Sci; 2022; 18(1):96-111. PubMed ID: 34975320
    [No Abstract]   [Full Text] [Related]  

  • 14. PTPN14 deficiency alleviates podocyte injury through suppressing inflammation and fibrosis by targeting TRIP6 in diabetic nephropathy.
    Lin Y; Shao Z; Zhao M; Li J; Xu X
    Biochem Biophys Res Commun; 2021 Apr; 550():62-69. PubMed ID: 33684622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA-binding proteins tristetraprolin and human antigen R are novel modulators of podocyte injury in diabetic kidney disease.
    Guo J; Lei M; Cheng F; Liu Y; Zhou M; Zheng W; Zhou Y; Gong R; Liu Z
    Cell Death Dis; 2020 Jun; 11(6):413. PubMed ID: 32487989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGFBP2 induces podocyte apoptosis promoted by mitochondrial damage via integrin α5/FAK in diabetic kidney disease.
    Wang X; Zhang Y; Chi K; Ji Y; Zhang K; Li P; Fu Z; Wang X; Cui S; Shen W; Cai G; Chen X; Zhu H; Hong Q
    Apoptosis; 2024 Aug; 29(7-8):1109-1125. PubMed ID: 38796567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p66Shc regulates podocyte autophagy in high glucose environment through the Notch-PTEN-PI3K/Akt/mTOR pathway.
    Zheng D; Tao M; Liang X; Li Y; Jin J; He Q
    Histol Histopathol; 2020 Apr; 35(4):405-415. PubMed ID: 31650524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplemented Gegen Qinlian Decoction Formula attenuates podocyte mitochondrial fission and renal fibrosis in diabetic kidney disease by inhibiting TNF-α-mediated necroptosis, compared with empagliflozin.
    Wang Y; Yu L; Li Y; Cha S; Shi L; Wang J; Ge F; Huang C; Huang H; Tu Y; Wan Y; Shen S
    J Ethnopharmacol; 2024 Nov; 334():118572. PubMed ID: 39025164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
    Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
    Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes.
    Chen D; Liu Y; Chen J; Lin H; Guo H; Wu Y; Xu Y; Zhou Y; Zhou W; Lu R; Zhou J; Wu J
    Eur J Pharmacol; 2021 Jul; 902():174121. PubMed ID: 33901462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.